A fund trimmed its position in Johnson & Johnson (JNJ) stock and disclosed the transaction via financial filings with the SEC.
3 reports, 1 independent
Updated Oct 6
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A fund trimmed its position in Johnson & Johnson (JNJ) stock and disclosed the transaction via financial filings with the SEC.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Trustee reduced JNJ shares, Amundi boosted position, and HSBC released research reports.1 source
Fund reduced JNJ holdings and filed with the SEC.1 source
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
SEC
Slovak company
Related events
- Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.
- Insider transactions were disclosed in an SEC filing, showing a hedge fund bought a new stake in Strategy Inc stock.
- Goldman Sachs CEO David M. Solomon sold shares and filed the transaction with the SEC.
- Surgery Partners and Fifth Third Bancorp announced increased holdings in company stock, requiring filing with the SEC on September 8, 2026.
- A fund prospectus was filed with the SEC, and Eli Lilly now constitutes about 17% of assets in the Health Care Select Sector SPDR Fund.